FWBI Key Statistics, Chart & Performance
The current stock price of FWBI is 2.96 USD. In the past month the price increased by 4.23%. In the past year, price decreased by -93.21%.
FWBI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FWBI. When comparing the yearly performance of all stocks, FWBI is a bad performer in the overall market: 98.3% of all stocks are doing better.
FWBI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to FWBI. Both the profitability and financial health of FWBI have multiple concerns.
FWBI Financial Highlights
Over the last trailing twelve months FWBI reported a non-GAAP Earnings per Share(EPS) of -88.75. The EPS increased by 75.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -233.87% | ||
| ROE | -446.8% | ||
| Debt/Equity | 0.17 |
FWBI Forecast & Estimates
8 analysts have analysed FWBI and the average price target is 36.72 USD. This implies a price increase of 1140.54% is expected in the next year compared to the current price of 2.96.
FWBI Ownership
FWBI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 383.08B | ||
| AMGN | AMGEN INC | 15.09 | 177.71B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.28 | 111.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.48 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.43 | 47.46B | ||
| INSM | INSMED INC | N/A | 33.97B | ||
| NTRA | NATERA INC | N/A | 33.17B | ||
| BIIB | BIOGEN INC | 10.07 | 24.73B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.83B | ||
| INCY | INCYTE CORP | 16.39 | 20.66B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.89 | 20.32B |
Related stock screener links
About FWBI
Company Profile
First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.
Company Info
FIRST WAVE BIOPHARMA
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
CEO: James Sapirstein
Employees: 10
Phone: 15615897020
FIRST WAVE BIOPHARMA / FWBI FAQ
What does FIRST WAVE BIOPHARMA do?
First Wave BioPharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2016-10-11. First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The firm is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. The company is focused on developing its pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, which is an oral small molecule with anti-viral and anti-inflammatory properties. Its adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company is advancing two separate Phase 2 clinical programs of its niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 GI infections, and FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis.
Can you provide the latest stock price for FIRST WAVE BIOPHARMA?
The current stock price of FWBI is 2.96 USD. The price increased by 4.59% in the last trading session.
Does FWBI stock pay dividends?
FWBI does not pay a dividend.
What is the ChartMill rating of FIRST WAVE BIOPHARMA stock?
FWBI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What sector and industry does FIRST WAVE BIOPHARMA belong to?
FIRST WAVE BIOPHARMA (FWBI) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for FIRST WAVE BIOPHARMA?
FIRST WAVE BIOPHARMA (FWBI) has a market capitalization of 4.62M USD. This makes FWBI a Nano Cap stock.